socio-behavioral characteristics in the context of DAA: Results ... - PLOS

2 downloads 0 Views 1MB Size Report
Jul 5, 2018 - Bourgogne, Dijon, France, 7 Université Paris Descartes, INSERM U-1223, Institut ... 0.0003), regular or daily use of cannabis (24.3% vs. 15.6% ...
RESEARCH ARTICLE

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

OPEN ACCESS Citation: Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, et al. (2018) Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS ONE 13(7): e0199874. https://doi. org/10.1371/journal.pone.0199874 Editor: Yury E. Khudyakov, Centers for Disease Control and Prevention, UNITED STATES Received: September 7, 2017 Accepted: June 15, 2018 Published: July 5, 2018 Copyright: © 2018 Yaya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Data for the statistical analysis are available from the scientific committee of the ANRS CO13-HEPAVIH cohort. The contact information for an institutional body to which data requests may be sent is as follows: Maria-Patrizia Carrieri, AMU, INSERM U1252, ORS PACA, IHU, 19 – 21 Boulevard Jean Moulin 13005, Marseille, France; E-mail: [email protected]. Funding: This work was supported by the French National Agency for Research on AIDS and Viral

Issifou Yaya1,2*, Perrine Roux1,2, Fabienne Marcellin1,2, Linda Wittkop3,4, Laure Esterle3, Bruno Spire1,2, Ste´phanie Dominguez5, Boni Armand Elegbe1,2, Lionel Piroth6, Philippe Sogni7, Dominique Salmon-Ceron8, Maria Patrizia Carrieri1,2, the ANRS CO13 HEPAVIH Study Group¶ 1 Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sante´ & Traitement de l’Information Me´dicale, Marseille, France, 2 ORS PACA, Observatoire re´gional de la sante´ ProvenceAlpes-Coˆte d’Azur, Marseille, France, 3 Univ. Bordeaux, ISPED, INSERM, Bordeaux Population Health Research Center, team MORPH3EUS, UMR 1219, CIC-EC 1401, Bordeaux, France, 4 CHU de Bordeaux, Pole de sante publique, Service d’information medicale, Bordeaux, France, 5 INSERM U955, AP-HP, Groupe Henri-Mondor Albert-Chenevier, Immunologie Clinique et Maladies Infectieuses, Cre´teil, France, 6 De´partement d’Infectiologie, Centre Hospitalier Universitaire and INSERM CIC 1432, Universite´ de Bourgogne, Dijon, France, 7 Universite´ Paris Descartes, INSERM U-1223, Institut Pasteur, Service d’He´patologie, hoˆpital Cochin, Assistance Publique–Hoˆpitaux de Paris, Paris, France, 8 Universite´ Paris Descartes, Service Maladies Infectieuses et Tropicales, AP-HP, Hoˆpital Cochin, Paris, France ¶ The ANRS CO13 HEPAVIH Study Group is presented in the Acknowledgments section. * [email protected]

Abstract Background Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment.

Methods ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV treatment initiation.

Results A total of 580 patients were included in this analysis. Of these, 347 initiated PEG-IFN-based treatment, and 233 DAA-based treatment. There were significant differences regarding patient mean age (45 years±6 for the PEG-IFN group vs. 52 years±8 for the DAA group, p